Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
Biotech TV interviews Christer Ahlberg
Interview with Cinclus Pharma’s CEO Christer Ahlberg on Biotech TV at the Pareto Healthcare Conference in Stockholm.
Cinclus Pharma at Aktiedagarna in Stockholm
Watch the presentation by Jesper Wiklund, Director of Corporate and Business Development at Cinclus Pharma, from Aktiedagarna in Stockholm September 17th (in Swedish).
Cinclus Pharma’s CEO Christer Ahlberg in interview with EFN Ekonomikanalen
Cinclus Pharma’s CEO Christer Ahlberg speaks in an interview with EFN Ekonomikanalen about the progress of the drug candidate linaprazan glurate, the strategic partnership with Zentiva, and the ongoing Phase III clinical trials (in Swedish).
Improving the quality of life for more people
Highlights from the 2024 Annual Report: Sustainability. Driving the development of medicines that can alleviate and cure globally prevalent diseases is Cinclus Pharma’s main contribution to improved public health and social sustainability.
Cinclus Pharma in media
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
2024-09-23Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
